Magnesium and Dexmedetomidine in Pheochromocytoma

N/ACompletedNCT05102058

Istanbul University108 enrolled

Overview

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Study Type

OBSERVATIONAL

Enrollment

108

Conditions

Phaeochromocytoma Crisis Hemodynamic Instability

Interventions

Magnesium-DexmedetomidineDRUG

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * American Society of Anesthesiologists classification (ASA) 1-3 * high urinary catecholamine or metabolites * tumor sizes \< 5 cm * body mass index (BMI) \<35 kg/m2 Exclusion Criteria: * open surgery * bilateral masses * tumor larger than 5 cm * incomplete data

Outcomes

Primary Outcomes

Sodium nitroprusside (SNP) requirement

intraoperative hypertensive episodes requiring SNP therapy

Time frame: intraoperative period

Secondary Outcomes

vasoactive therapy

hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.

Time frame: intraoperative period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.